Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Columbia Laboratories (AMEX:COB)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug  8Earnings Announcement
Location
100 North Village Ave., Suite 32
Rockville Centre, NY 11570
Phone: (516) 766-2847
Fax: (516) 766-2873
Employees (last reported count): 27
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Website
 ·Home Page

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 20%
·Over the last 6 months:
 · one insider buy; 20.0K shares (0.3% of insider shares)
 · 2 insider sells; 125.0K shares
  (1.9% of insider shares)
·Institutional: 32% (40% of float)
(101 institutions)
·Net Inst. Buying: 531.0K shares (+4.97%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Columbia Laboratories, Inc. develops pharmaceutical products that treat female specific diseases and conditions including infertility, dysmenorrhea, endometriosis and hormonal deficiencies. Columbia's research in endocrinology has also led to the development of a product to treat Andropause in men. Columbia's products primarily utilize the Company's patented bioadhesive delivery technology, the Bioadhesive Delivery System. Formulated products utilizing the Bioadhesive Delivery System consist principally of a polymer, polycarbophil and an active ingredient. The Bioadhesive Delivery System is based upon the principle of bioadhesion, a process by which the polymer adheres to epithelial surfaces and to mucin, a naturally occurring secretion of the mucous membranes.
More from Market Guide: Expanded Business Description

Financial Summary
COB develops pharmaceutical products for female diseases including infertility, hormonal deficiencies, dysmenorrhea, endometriosis, and STD using patented bio-adhesive delivery technology. For the six months ended 6/30/01, sales fell 78% to $1.3 million. Net loss applicable to Common totaled $8.4 million, up from $2.7 million. Revenues reflect lower sales of Crinone. Higher loss also reflects the costs associated with Phase III trials and product recalls.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Compensation
PayExer

William Bologna, 58
Chairman
$400K--  
G. Frederick Wilkinson, 45
Pres, CEO
--  --  
James Apostolakis, 58
Vice Chairman
200K--  
David Weinberg, 55
VP- Fin. and Admin., CFO, Sec. and Treasurer
200K--  
Dominique De Ziegler, 53
VP- Pharmaceutical Devel.
210K$600K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year.
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- AMEX:COBAs of 31-Aug-2001
Price and Volume
52-Week Low
on 21-Dec-2000
$3.125
Recent Price$5.55 
52-Week High
on 28-June-2001
$8.40 
Beta1.22 
Daily Volume (3-month avg)80.5K
Daily Volume (10-day avg)43.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-2.4%
52-Week Change
relative to S&P500
+30.9%
Share-Related Items
Market Capitalization$175.0M
Shares Outstanding31.5M
Float25.2M
Dividends & Splits
Annual Dividendnone 
Last Split: 21 for 20 on 6-May-1996
Per-Share Data
Book Value (mrq)-$0.05 
Earnings (ttm)-$0.28 
Earnings (mrq)-$0.14 
Sales (ttm)$0.28 
Cash (mrq)$0.22 
Valuation Ratios
Price/BookN/A 
Price/EarningsN/A 
Price/Sales (ttm)19.46 
Income Statements
Sales (ttm)$8.74M
EBITDA (ttm)-$6.44M
Income available to common (ttm)-$8.52M
Profitability
Profit Margin (ttm)-95.1%
Operating Margin (ttm)-81.4%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-55.96%
Return on Equity (ttm)-426.56%
Financial Strength
Current Ratio (mrq)2.66 
Debt/EquityN/A 
Total Cash (mrq)$6.78M
Short Interest
As of 8-Aug-2001
Shares Short1.20M
Percent of Float4.8%
Shares Short
(Prior Month)
0 
Short Ratio13.79 
Daily Volume87.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.